UNSPSC 51371905: Isomethadone

This classification denotes an opioid receptor agonist with the molecular formula C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12L95QD6KV, chemically known as 1,1-diphenyl-1-(dimethylaminoisopropyl)butanone-2 but generally known as isomethadone, which bears US NIH Compound Identifier 10072. European Medicines Agency schedules Isomethadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08323MIG. The term ISOMETHADONE is an International Non-Proprietary Name.

UNSPSC 51371905 Isomethadone is a Commodity code that in practice covers pharmaceutical procurement spanning naloxone, opioid antagonists, and other controlled or prescription-based substances acquired by state and local health agencies. Recent state and local solicitations under this code focus on naloxone acquisition and safe drug deactivation systems for community health and harm-reduction initiatives, though the code's breadth extends to generic pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances serving state and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Solicitations range from straightforward IFB notices for naloxone and drug deactivation systems to complex RFP processes for statewide or multistate pharmaceutical supply agreements and exploratory RFIs gathering market intelligence on direct-to-manufacturer contracting models.

Recent activity spans Florida, Texas, and Minnesota, with the MMCAP procurement extending to Oregon and other cooperative members. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year term plus one-year renewal option; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with contract effectiveness July 1, 2026, and a two-year initial term. Vendors pursuing MMCAP awards face price-weighted evaluation (75 percent weight on competitiveness), mandatory compliance with cGMP and Drug Supply Chain Security Act requirements, and performance penalties of $200 to $1,500 per violation.